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background: We have previously demonstrated that spontaneously atherosclerotic, familial hypercholestrolemic swine (FHS) model is predictive of 
antirestenotic effects of established and experimental paclitaxel coated balloons (PCB) in peripheral arteries (JACC Interv 2012). However, the utility 
of this model in testing efficacy of coronary interventional therapies is less certain. We aimed to demonstrate differential antirestenotic effects of 
established and experimental variants of the PCB vs. uncoated angioplasty balloon utilizing bare metal stents (BMS) premounted on these balloons 
in the coronary arteries of FHS.
Methods: Twenty-one coronary arteries of 8 FHS were treated with BMS premounted on one clinically proven PCB (Paccocath, 3.08 μg 
paclitaxel/1.97 μg iopromide per mm2 of balloon surface; n=5), one experimental PCBs featuring 1/3 drug dose (PCB1, n=5), one experimental PCB 
featuring 3.08 μg paclitaxel/15 μg iopromide per mm2 of balloon surface (PCB2, n=6), and a control uncoated balloon (n=5). After 28 days coronary 
re-narrowing was assessed by IVUS and histology.
results: At 28 days, neointimal area (mm2) by IVUS was consistently lower in all 3 PCB-treated groups (Paccocath: 2.71±1.38*, PCB1: 
2.26±1.02*, PCB2: 1.69±1.35 mm2*, *p<0.05 vs. control) compared to the control (5.37±1.42 mm2). Similarly, all 3 PCBs showed average 
percentage area of stenosis by IVUS under 30% (Paccocath: 29.5±15.9%*, PCB1: 25.7±15.3%*, PCB2: 19.8±16.1%*, *p<0.05 vs. control), while 
the control had an average of nearly 50% (49.9±13.5 %). The IVUS results were confirmed by histology; all PCBs reduced neointimal thickness (mm) 
in comparison to control (Paccocath: 0.26±0.07*, PCB1: 0.31±0.09, PCB2, 0.26±0.06*, control 0.59±0.15, *p<0.05 vs. control).
conclusions: The spontaneously atherosclerotic FHS model is predictive of antirestenotic efficacy of established and experimental paclitaxel 
coated balloons (PCB) in coronary arteries. As such, it overcomes significant shortcoming of commonly used normal porcine coronary vasculature 
whose predictive value is well established for safety endpoints but generally very limited in regard to potential antirestenotic efficacy.
